Waldencast (WALD) Stock Price, News & Analysis

Company Overview

Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians. The company also offers clean makeup products under the Milk Makeup brand. It sells its products to dermatologists, plastic surgeons, and other physicians who focuses on aesthetic and therapeutic skincare, including physicians on site at medical spas, through its direct sales force, as well as through distribution partners. The company is headquartered in White Plains, New York.

Key Stats

• Today's Range: $1.34 to $1.40
• 50-Day Range: $1.39 to $1.87
• 52-Week Range: $0.72 to $3.22
• Volume: 36,275 shs
• Average Volume: 664,287 shs
• Market Capitalization: $172.32 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $2.33
• Consensus Rating: Hold

Waldencast Stock Analysis - MarketRank™

Waldencast scored higher than 47% of companies evaluated by MarketBeat, and ranked 112th out of 170 stocks in the consumer staples sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Waldencast has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Waldencast has a consensus price target of $2.33, representing about 74.1% upside from its current price of $1.34.

Amount of Analyst Coverage

Waldencast has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Waldencast has a P/B Ratio of 0.34. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.11% of the float of Waldencast has been sold short.

Short Interest Ratio / Days to Cover

Waldencast has a short interest ratio ("days to cover") of 0.33, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Waldencast has recently decreased by 21.93%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Waldencast does not currently pay a dividend.

Dividend Growth

Waldencast does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Waldencast this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for WALD on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Waldencast insiders have not sold or bought any company stock.

Percentage Held by Institutions

41.97% of the stock of Waldencast is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Today: 8/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Consumer Staples
• Industry: Personal Care Products
• Sub-Industry: Personal Care Products
• Current Symbol: NASDAQ:WALD
• CIK: 1840199
• Web: www.waldencast.com
• Phone: 917-546-6828
• Fax: N/A
• Employees: 272
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Waldencast: $2.33
• High Price Target: $3.00
• Low Price Target: $2.00
• Potential Upside/Downside: +73.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.29
• Current Ratio: 1.70
• Quick Ratio: 0.97

Sales & Book Value

• Annual Sales: $272.07 million
• Price / Sales: 0.64
• Cash Flow: $0.06 per share
• Price / Cash Flow: 21.68
• Book Value: $3.90 per share
• Price / Book: 0.34

Miscellaneous

• Outstanding Shares: 128,600,000
• Free Float: N/A
• Market Cap: $172.97 million
• Optionable: Not Optionable
• Beta: -0.13